Arcus Biosciences (RCUS) Retained Earnings (2017 - 2026)

Arcus Biosciences' Retained Earnings history runs 10 years deep, the most recent figure standing at -$1.6 billion for Q1 2026.

• In Q1 2026, Retained Earnings fell 29.66% year-over-year to -$1.6 billion; the TTM figure through Mar 2026 stood at -$1.6 billion (down 29.66% YoY), while the FY2024 annual figure was -$1.1 billion, down 33.33% from the prior year.
• Retained Earnings for Q1 2026 stood at -$1.6 billion, down from -$1.4 billion in the prior quarter.
• The five-year high for Retained Earnings was $1.2 billion in Q3 2022, with the low at -$1.6 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$808.5 million (2023), against an average of -$553.2 million.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings jumped 313.33% in 2022, then slumped 138000.0% in 2025.
• Arcus Biosciences' Retained Earnings stood at -$542.0 million in 2022, then slumped by 56.64% to -$849.0 million in 2023, then plunged by 33.33% to -$1.1 billion in 2024, then decreased by 21.82% to -$1.4 billion in 2025, then retreated by 16.97% to -$1.6 billion in 2026.
• Business Quant data shows RCUS's Retained Earnings at -$1.6 billion in Q1 2026, -$1.4 billion in Q3 2025, and -$1.2 billion in Q2 2025.